COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00917059
Recruitment Status : Completed
First Posted : June 10, 2009
Last Update Posted : February 6, 2013
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Ian A. Cook, M.D., University of California, Los Angeles

Brief Summary:
This study will examine whether measures of brain electrical signals taken after a week of antidepressant medication treatment can predict whether a full treatment regimen will be effective.

Condition or disease Intervention/treatment Phase
Depression Drug: Escitalopram Drug: Bupropion XL Phase 4

Detailed Description:

Major depressive disorder (MDD) is a common psychiatric illness with a high cost to society and individual patients. Initial medication treatments for MDD are often ineffective, precipitating a need to try other medications. This extends suffering, continues functional disability, and increases both the risk of relapse and the risk that people will abandon treatment. Having a biological marker of likely treatment effectiveness to predict and guide clinicians' decisions would reduce the likelihood of people with MDD experiencing unsuccessful treatments. This study will test whether quantitative electroencephalogram (QEEG) measures taken after 1 week of medication treatment can predict effectiveness of a full treatment regimen with depression medications.

Participation in this study will last 8 weeks. At the first study visit, participants will undergo baseline assessments. These assessments will include an interview about present condition, medical and psychiatric history, and past and current medication treatments; a urine test; and questionnaires about depression symptoms and other possible symptoms. The study doctor may ask for other assessments based on each participant's individual profile.

Participants will then complete a 1-week treatment with escitalopram, a type of antidepressant medication called a selective serotonin reuptake inhibitor (SSRI). At the first visit and again after the week-long escitalopram treatment, participants will undergo an electroencephalogram (EEG), which measures brain electrical activity. Based on certain measurements obtained from the EEG, an antidepressant treatment response (ATR) score will be calculated.

Participants will then be divided into two treatment groups: those who continue to receive escitalopram and those who begin treatment with bupropion XL, a non-SSRI antidepressant medication. Treatment for both groups will last 8 weeks, during which time participants will attend seven study visits. At these study visits, participants will be asked about how they are feeling, side effects, and benefit from the treatment. Further tests-such as a physical exam, lab test, or EEG-may be performed if study doctors think they are necessary.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 172 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Personalized Response Indicators of SSRI Effectiveness in Major Depression
Study Start Date : May 2009
Actual Primary Completion Date : May 2012
Actual Study Completion Date : May 2012

Arm Intervention/treatment
Active Comparator: 1
Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
Drug: Escitalopram
Fixed dose of 10 mg per day
Other Name: Lexapro

Active Comparator: 2
Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
Drug: Escitalopram
Fixed dose of 10 mg per day
Other Name: Lexapro

Drug: Bupropion XL
Fixed dose of 150 mg per day
Other Name: Wellbutrin XL

Primary Outcome Measures :
  1. Score on Hamilton Depression Rating Scale (HAM-D) [ Time Frame: Measured nine times over 8 weeks ]

Secondary Outcome Measures :
  1. Score on Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) [ Time Frame: Measured nine times over 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets DSM-IV criteria for diagnosis of major depressive disorder (MDD) based on the Mini-International Neuropsychiatric Interview (MINI)
  • Score greater than or equal to 12 on the Quick Inventory of Depressive Symptomatology - Self Rated version (QIDS-SR16)

Exclusion Criteria:

  • Serious or unstable medical illness that would prevent complete participation in the trial, determined as needed from physical examination, electrocardiogram (ECG), laboratory safety tests, and review of systems
  • Mentally or legally incapacitated and therefore unable to give informed consent
  • Meets DSM-IV criteria for anorexia nervosa, bulimia nervosa, obsessive-compulsive disorder, any cognitive disorder, bipolar disorder, psychotic disorder, or major depression with psychotic features
  • Diagnosis of a DSM-IV axis II disorder that would interfere with completion of the protocol
  • Would have met criteria for a diagnosis of drug dependency or substance abuse within the preceding 9 months
  • Stable and in remission on current psychotropic medication(s)
  • Has had a course of electroconvulsive therapy (ECT) within the past 6 months
  • Started psychotherapy for the current depressive episode within the past 2 months
  • Has experienced treatment failure with an adequate trial of any study medication during the current episode of depression or has failed to tolerate escitalopram in the current episode
  • Known contraindication for use of any of the study drugs, including hyponatremia during past use of a selective serotonin reuptake inhibitor (SSRI)
  • Treated with fluoxetine or a monoamine oxidase inhibitor (MAOI) within the past 4 weeks
  • Presence of a serious or unstable medical illness, including heart, liver, kidney, respiratory, endocrine, neurologic, or blood disease severe enough to significantly affect brain function or to interfere with interpretation of study results
  • History of seizures, brain surgery, skull fracture, significant head trauma, or abnormal electroencephalogram (EEG)
  • Currently pregnant or of childbearing potential and not using a medically acceptable means of birth control (e.g., oral contraceptive pill or implant, condom, diaphragm, spermicide, intrauterine device [IUD], past tubal ligation, partner with vasectomy)
  • Breastfeeding
  • University student or staff member directly under instruction, supervision, or employment of any of the investigators
  • Requires hospitalization (e.g., poses an imminent danger to self or others)
  • Initial quantitative EEG (QEEG) is contaminated with artifact so that determination of the biomarker is precluded
  • Use of medications known to affect brain function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00917059

Layout table for location information
United States, California
UCLA Semel Institute
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Ian A. Cook, MD University of California, Los Angeles
Layout table for additonal information
Responsible Party: Ian A. Cook, M.D., University of California, Los Angeles Identifier: NCT00917059    
Other Study ID Numbers: R01MH085925 ( U.S. NIH Grant/Contract )
R01MH085925 ( U.S. NIH Grant/Contract )
First Posted: June 10, 2009    Key Record Dates
Last Update Posted: February 6, 2013
Last Verified: February 2013
Keywords provided by Ian A. Cook, M.D., University of California, Los Angeles:
Major Depressive Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors